---
title: Receptor Occupancy (RO) Assays by Flow Cytometry | CBS
description: "Receptor occupancy (RO) assay services by flow cytometry: free, bound and total receptor formats, method validation and clinical sample analysis in Pleasanton, CA."
image: https://www.crystalbiosolutions.com/hubfs/CBS%20lab/DSCF0117-min.jpg
---

![Crystal Bio Solutions logo](https://www.crystalbiosolutions.com/hs-fs/hubfs/Crystal%20Bio%20Solutions%20logo.webp?width=330&height=150&name=Crystal%20Bio%20Solutions%20logo.webp)

- Bioanalysis & Biomarkers 
    - [All Bioanalysis & Biomarker Services](https://www.crystalbiosolutions.com/services/bioanalysis-and-biomarkers)
    - [PK Assays for Biologics & ADCs](https://www.crystalbiosolutions.com/services/pk-bioanalysis)
    - [NAb & ADA Immunogenicity Assays](https://www.crystalbiosolutions.com/ada-and-nab-testing-in-biologics-pk-efficacy-and-regulatory-risk)
    - [Receptor Occupancy Assays](https://www.crystalbiosolutions.com/services/receptor-occupancy-assays)
- Biologics CMC Analytical 
    - [All Biologics CMC Analytical Services](https://www.crystalbiosolutions.com/characterization-cmc-analytical)
    - [Developability Assessment](https://www.crystalbiosolutions.com/services/biologics-developability-assessment)
    - [Extended Characterization by HRMS](https://www.crystalbiosolutions.com/services/biologics-extended-characterization-hrms)
    - [Biotransformation & In Vivo CQA](https://www.crystalbiosolutions.com/services/biotransformation-in-vivo-cqa)
- [Clinical Pharmacology](https://www.crystalbiosolutions.com/services/clinical-pharmacology)
- Solutions 
    - [ADC Programs](https://www.crystalbiosolutions.com/antibody-drug-conjugates-adc)
    - [Regulatory Affairs Support](https://www.crystalbiosolutions.com/services/regulatory-affairs-biologics-adc-cgt)
    - [Clinical Support](https://www.crystalbiosolutions.com/clinical-research-services)

- [Resources](https://www.crystalbiosolutions.com/news-and-events)
- [Case Studies](https://www.crystalbiosolutions.com/news-and-events/tag/case-study)
- [About Us](https://www.crystalbiosolutions.com/about-us)
- [Locations](https://www.crystalbiosolutions.com/locations)
- [Careers](https://www.crystalbiosolutions.com/careers-at-crystal-bio-solutions)
- [Request a Proposal](https://www.crystalbiosolutions.com/contact-us)

![Scientist loading a 96-well plate with a multichannel pipette during bioanalysis sample preparation.](https://www.crystalbiosolutions.com/hs-fs/hubfs/bioanalytical-and-biomarker.webp?width=960&height=640&name=bioanalytical-and-biomarker.webp)

# Receptor Occupancy Assays by Flow Cytometry

Receptor occupancy (RO) assays measure how much of a drug's target is bound on cells, linking drug exposure to target engagement. Crystal Bio Solutions, part of Crystal Group, designs, qualifies and validates flow cytometry RO assays for antibody therapeutics and analyzes clinical samples in our GLP- and GCLP-compliant bioanalysis laboratory in Pleasanton, California. RO results are interpreted together with PK, immunogenicity and biomarker data to support dose selection.

[![Let's talk](https://hubspot-no-cache-eu1-prod.s3.amazonaws.com/cta/default/146565877/interactive-264126601418.png)](https://www.crystalbiosolutions.com/hs/cta/wi/redirect?encryptedPayload=AVxigLL6gJVKP2GYNoLIR707Arlbg1Xp7ePBkF%2FTUK1i8uFvY0rySgKvS0CzTKxV%2FTMyNnsUz%2Fc6lMJcLjvOM348S%2BaRpj2C9XJwEcEkEnaFHQRlJs05aMIJVyB%2BByht%2BZRf2YcqnvC463sYX%2FBQpjKuwnFQNNlkko1%2FaJQnFAJe%2FFv68DmNsJYwfNn4lqsJ4XcI%2B2vyjVcVhgrpQwxDV%2B85Pj57wuOy&webInteractiveContentId=264126601418&portalId=146565877&hsLang=en)

![CBS orange-blue banner-1](https://www.crystalbiosolutions.com/hs-fs/hubfs/CBS%20orange-blue%20banner-1.png?width=2000&height=21&name=CBS%20orange-blue%20banner-1.png "CBS orange-blue banner-1")

Assay Format Selection Free-receptor, drug-bound (occupied) and total-receptor formats, chosen according to the drug's mechanism, receptor biology and the availability of competing or non-competing detection reagents. Panel and Reagent Design Multiparameter flow cytometry panels that identify the relevant cell populations, with controls and compensation, viability tracking, and evaluation of critical reagents. Qualification and Validation Phase-appropriate qualification or validation covering precision, drug-dependent response, sensitivity, specificity and sample stability, documented for regulatory review. Sample Stability and Logistics Stability studies that define the collection-to-analysis window, plus central lab kit design, cold-chain logistics and chain-of-custody tracking for multi-site clinical studies. Clinical Sample Analysis Analysis of clinical samples under our GLP/GCLP quality system, with standardized data packages and reports formatted for regulatory submission. PK/PD Interpretation RO data related to drug concentrations, ADA results and other biomarkers, with support from our clinical pharmacology team for exposure-response and dose selection.

![CBS orange banner-1](https://www.crystalbiosolutions.com/hs-fs/hubfs/website-assets/CBS%20orange%20banner-1.png?width=2000&height=24&name=CBS%20orange%20banner-1.png "CBS orange banner-1")

![Scientist working in a bioanalysis laboratory](https://www.crystalbiosolutions.com/hs-fs/hubfs/pexels-pavel-danilyuk-8442153.jpg?width=640&height=480&name=pexels-pavel-danilyuk-8442153.jpg) Case Study: PD-1 Receptor Occupancy Assay Crystal Bio Solutions established a flow cytometry RO assay for an anti-PD-1 antibody and validated it for clinical analysis.

**Highlights:**

- No detection antibody that competes with the drug was available, so the assay used the occupied-receptor format
- Total receptor was measured in the same sample to correct for changes in baseline receptor expression
- Intra- and inter-run precision below 8% CV at high, medium and low QC levels
- Drug-dependent linearity across the relevant concentration range
- Sample stability up to 3 days after collection, supporting multi-site clinical logistics

## Related Services

Bioanalysis & Biomarkers PK, immunogenicity and biomarker assays for biologics and novel modalities. PK Assays for Biologics and ADCs Total antibody, conjugated drug and free payload assays by LBA and LC-MS. NAb and ADA Assays Immunogenicity assay development, validation and sample analysis. Clinical Pharmacology PK/PD modeling, exposure-response and dose selection.

## Frequently Asked Questions

 

### What is a receptor occupancy assay?

A receptor occupancy (RO) assay measures the fraction of a drug's target receptor that is bound by the drug, usually on circulating blood cells. It shows whether the drug engages its target on those cells at the doses tested and is used as a pharmacodynamic biomarker, especially for immunomodulatory antibodies. Using occupancy on circulating cells to infer engagement in tissue requires separate justification.

 

### What are the free, bound and total receptor formats?

The free-receptor format uses a detection reagent that competes with the drug, so it detects only unoccupied receptor. The bound (occupied) format detects the drug on the cell surface, for example with an anti-drug antibody. The total-receptor format uses a non-competing reagent to measure all receptor, bound or not. Combining formats lets occupancy be calculated while correcting for changes in receptor expression.

 

### Why is flow cytometry used for receptor occupancy?

Flow cytometry measures receptor binding on individual cells and can restrict the measurement to the relevant cell population, such as specific T-cell subsets, within a whole-blood sample. Multiparameter panels allow occupancy and cell phenotype to be assessed in one assay.

 

### What are the main challenges in developing an RO assay?

Common challenges include low receptor expression, the availability of suitable competing or non-competing detection reagents, receptor internalization or shedding after drug binding, limited sample stability, and variability between donors and sites. Format selection and stability studies address these early in development.

 

### How long are samples stable for receptor occupancy analysis?

Stability depends on the target, cell type and sample handling, so it is established for each assay during qualification or validation. In a CBS PD-1 RO assay, samples were stable for up to 3 days after collection, which supported shipment from clinical sites.

 

### How are RO data used in dose selection?

RO data show the relationship between drug concentration and target engagement. Together with PK, ADA and efficacy biomarkers, they help define doses and schedules that maintain the intended level of occupancy, and they are often used in exposure-response and population PK/PD modeling.

 

### Does Crystal Bio Solutions run RO assays for clinical studies?

Yes. CBS designs, qualifies and validates flow cytometry RO and immunophenotyping assays and analyzes clinical samples in its GLP- and GCLP-compliant laboratory in Pleasanton, California, with central lab kit and logistics support available.

 

## Related case studies

- [Receptor Occupancy of an Antibody Drug Measured by Flow Cytometry](https://www.crystalbiosolutions.com/news-and-events/receptor-occupancy-of-antibody-drug-measured-by-flow-cytometry?hsLang=en): Flow cytometry measurement of receptor occupancy for an antibody drug.
- [Immunophenotyping to Identify Peripheral Lymphocyte Subsets](https://www.crystalbiosolutions.com/news-and-events/immunophenotyping-to-identify-peripheral-lymphocyte-subsets?hsLang=en): A flow cytometry panel to identify peripheral lymphocyte subsets.

[See all case studies](https://www.crystalbiosolutions.com/news-and-events/tag/case-study?hsLang=en)

Discuss your assay with Dr. Meina Liang, our Chief Scientific Officer

Bring a real PK, immunogenicity, receptor occupancy or biomarker problem to the leader who supervises our bioanalysis projects. One hour at no cost, with a CDA in place first. Our business development team replies within one business day.

[Request a Consultation](https://www.crystalbiosolutions.com/scientific-consultation?hsLang=en)

## Ready to Start a Project?

Tell us about your study. Our business development team replies within one business day.

[Request a Proposal](https://www.crystalbiosolutions.com/contact-us?hsLang=en)

![Crystal Bio Solutions logo (footer)](https://www.crystalbiosolutions.com/hubfs/Logo_CBS-%E7%AB%96%E7%89%88-%E5%8F%8D%E7%99%BD.png)

- [Our Services](https://www.crystalbiosolutions.com) 
    - [Bioanalysis & Biomarkers](https://www.crystalbiosolutions.com/services/bioanalysis-and-biomarkers)
    - [Biologics CMC Analytical](https://www.crystalbiosolutions.com/characterization-cmc-analytical)
    - [Clinical Pharmacology](https://www.crystalbiosolutions.com/services/clinical-pharmacology)
    - [Regulatory Affairs](https://www.crystalbiosolutions.com/services/regulatory-affairs-biologics-adc-cgt)
    - [Clinical Support](https://www.crystalbiosolutions.com/clinical-research-services)
- [Information](https://www.crystalbiosolutions.com/news-and-events) 
    - [About Us](https://www.crystalbiosolutions.com/about-us)
    - [Quality & Compliance](https://www.crystalbiosolutions.com/quality-and-compliance)
    - [News & Events](https://www.crystalbiosolutions.com/news-and-events)
    - [Case Studies](https://www.crystalbiosolutions.com/news-and-events/tag/case-study)
    - [Scientific Articles](https://www.crystalbiosolutions.com/news-and-events/tag/blog)
    - [Careers](https://www.crystalbiosolutions.com/careers-at-crystal-bio-solutions)
- [Contact](https://www.crystalbiosolutions.com/contact-us) 
    - [Email Us](mailto:cbs_bd@crystalpharmatech.com)
    - [Contact Form](https://www.crystalbiosolutions.com/contact-us)
    - [Our Locations](https://www.crystalbiosolutions.com/locations)
    - [Crystal Group](https://www.crystalbiosolutions.com/about-us#crystal-group) 
          - [Crystal Pharmatech](https://www.crystalpharmatech.com/)
          - [Crystal NAX](https://www.crystalnax.com/)

<https://www.linkedin.com/company/crystal-bio-solutions/> [Follow us on LinkedIn News, events and openings](https://www.linkedin.com/company/crystal-bio-solutions/)

- [Privacy Policy](https://www.crystalbiosolutions.com/policies/privacy-policy)
- [Terms of Service](https://www.crystalbiosolutions.com/policies/terms-of-service)

Copyright © 2026 Crystal Bio Solutions, Inc. All rights reserved.

```json
{
  "@context" : "https://schema.org",
  "@id" : "https://www.crystalbiosolutions.com/#organization",
  "@type" : "Organization",
  "alternateName" : "CBS",
  "contactPoint" : [ {
    "@type" : "ContactPoint",
    "contactType" : "sales",
    "email" : "cbs_bd@crystalpharmatech.com",
    "url" : "https://www.crystalbiosolutions.com/contact-us"
  } ],
  "logo" : "https://www.crystalbiosolutions.com/hs-fs/hubfs/CBS%20VI%20v2/CBS%20Logo.png",
  "name" : "Crystal Bio Solutions",
  "parentOrganization" : {
    "@type" : "Organization",
    "name" : "Crystal Group",
    "url" : "https://www.crystalpharmatech.com/"
  },
  "sameAs" : [ "https://www.linkedin.com/company/crystal-bio-solutions/" ],
  "url" : "https://www.crystalbiosolutions.com/"
}
```

```json
{
  "@context" : "https://schema.org",
  "@id" : "https://www.crystalbiosolutions.com/#website",
  "@type" : "WebSite",
  "inLanguage" : "en",
  "name" : "Crystal Bio Solutions",
  "publisher" : {
    "@id" : "https://www.crystalbiosolutions.com/#organization"
  },
  "url" : "https://www.crystalbiosolutions.com/"
}
```

```json
{
  "@context" : "https://schema.org",
  "@id" : "https://www.crystalbiosolutions.com/services/receptor-occupancy-assays/#webpage",
  "@type" : "WebPage",
  "about" : {
    "@id" : "https://www.crystalbiosolutions.com/services/receptor-occupancy-assays/#service"
  },
  "breadcrumb" : {
    "@id" : "https://www.crystalbiosolutions.com/services/receptor-occupancy-assays/#breadcrumb"
  },
  "description" : "Flow cytometry receptor occupancy (RO) assay design, qualification and validation for antibody drugs, with free, bound and total receptor formats and PK/PD support.",
  "inLanguage" : "en",
  "isPartOf" : {
    "@id" : "https://www.crystalbiosolutions.com/#website"
  },
  "name" : "Receptor Occupancy Assays by Flow Cytometry | CBS",
  "url" : "https://www.crystalbiosolutions.com/services/receptor-occupancy-assays"
}
```

```json
{
  "@context" : "https://schema.org",
  "@id" : "https://www.crystalbiosolutions.com/services/receptor-occupancy-assays/#service",
  "@type" : "Service",
  "areaServed" : "Worldwide",
  "description" : "Design, qualification, validation and clinical sample analysis of flow cytometry receptor occupancy assays for antibody therapeutics, in a GLP- and GCLP-compliant laboratory.",
  "hasOfferCatalog" : {
    "@type" : "OfferCatalog",
    "itemListElement" : [ {
      "@type" : "Offer",
      "itemOffered" : {
        "@type" : "Service",
        "name" : "RO assay format selection (free, bound, total receptor)"
      }
    }, {
      "@type" : "Offer",
      "itemOffered" : {
        "@type" : "Service",
        "name" : "Flow cytometry panel and reagent design"
      }
    }, {
      "@type" : "Offer",
      "itemOffered" : {
        "@type" : "Service",
        "name" : "RO assay qualification and validation"
      }
    }, {
      "@type" : "Offer",
      "itemOffered" : {
        "@type" : "Service",
        "name" : "Sample stability and clinical logistics"
      }
    }, {
      "@type" : "Offer",
      "itemOffered" : {
        "@type" : "Service",
        "name" : "Clinical sample analysis"
      }
    }, {
      "@type" : "Offer",
      "itemOffered" : {
        "@type" : "Service",
        "name" : "PK/PD interpretation of RO data"
      }
    } ],
    "name" : "Receptor Occupancy Assays by Flow Cytometry"
  },
  "name" : "Receptor Occupancy Assays by Flow Cytometry",
  "provider" : {
    "@id" : "https://www.crystalbiosolutions.com/#organization"
  },
  "url" : "https://www.crystalbiosolutions.com/services/receptor-occupancy-assays"
}
```

```json
{
  "@context" : "https://schema.org",
  "@id" : "https://www.crystalbiosolutions.com/services/receptor-occupancy-assays/#breadcrumb",
  "@type" : "BreadcrumbList",
  "itemListElement" : [ {
    "@type" : "ListItem",
    "item" : "https://www.crystalbiosolutions.com/",
    "name" : "Home",
    "position" : 1
  }, {
    "@type" : "ListItem",
    "item" : "https://www.crystalbiosolutions.com/services/bioanalysis-and-biomarkers",
    "name" : "Bioanalysis & Biomarkers",
    "position" : 2
  }, {
    "@type" : "ListItem",
    "item" : "https://www.crystalbiosolutions.com/services/receptor-occupancy-assays",
    "name" : "Receptor Occupancy Assays",
    "position" : 3
  } ]
}
```

```json
{
  "@context" : "https://schema.org",
  "@id" : "https://www.crystalbiosolutions.com/services/receptor-occupancy-assays/#faq",
  "@type" : "FAQPage",
  "mainEntity" : [ {
    "@type" : "Question",
    "acceptedAnswer" : {
      "@type" : "Answer",
      "text" : "A receptor occupancy (RO) assay measures the fraction of a drug's target receptor that is bound by the drug, usually on circulating blood cells. It shows whether the drug engages its target on those cells at the doses tested and is used as a pharmacodynamic biomarker, especially for immunomodulatory antibodies. Using occupancy on circulating cells to infer engagement in tissue requires separate justification."
    },
    "name" : "What is a receptor occupancy assay?"
  }, {
    "@type" : "Question",
    "acceptedAnswer" : {
      "@type" : "Answer",
      "text" : "The free-receptor format uses a detection reagent that competes with the drug, so it detects only unoccupied receptor. The bound (occupied) format detects the drug on the cell surface, for example with an anti-drug antibody. The total-receptor format uses a non-competing reagent to measure all receptor, bound or not. Combining formats lets occupancy be calculated while correcting for changes in receptor expression."
    },
    "name" : "What are the free, bound and total receptor formats?"
  }, {
    "@type" : "Question",
    "acceptedAnswer" : {
      "@type" : "Answer",
      "text" : "Flow cytometry measures receptor binding on individual cells and can restrict the measurement to the relevant cell population, such as specific T-cell subsets, within a whole-blood sample. Multiparameter panels allow occupancy and cell phenotype to be assessed in one assay."
    },
    "name" : "Why is flow cytometry used for receptor occupancy?"
  }, {
    "@type" : "Question",
    "acceptedAnswer" : {
      "@type" : "Answer",
      "text" : "Common challenges include low receptor expression, the availability of suitable competing or non-competing detection reagents, receptor internalization or shedding after drug binding, limited sample stability, and variability between donors and sites. Format selection and stability studies address these early in development."
    },
    "name" : "What are the main challenges in developing an RO assay?"
  }, {
    "@type" : "Question",
    "acceptedAnswer" : {
      "@type" : "Answer",
      "text" : "Stability depends on the target, cell type and sample handling, so it is established for each assay during qualification or validation. In a CBS PD-1 RO assay, samples were stable for up to 3 days after collection, which supported shipment from clinical sites."
    },
    "name" : "How long are samples stable for receptor occupancy analysis?"
  }, {
    "@type" : "Question",
    "acceptedAnswer" : {
      "@type" : "Answer",
      "text" : "RO data show the relationship between drug concentration and target engagement. Together with PK, ADA and efficacy biomarkers, they help define doses and schedules that maintain the intended level of occupancy, and they are often used in exposure-response and population PK/PD modeling."
    },
    "name" : "How are RO data used in dose selection?"
  }, {
    "@type" : "Question",
    "acceptedAnswer" : {
      "@type" : "Answer",
      "text" : "Yes. CBS designs, qualifies and validates flow cytometry RO and immunophenotyping assays and analyzes clinical samples in its GLP- and GCLP-compliant laboratory in Pleasanton, California, with central lab kit and logistics support available."
    },
    "name" : "Does Crystal Bio Solutions run RO assays for clinical studies?"
  } ]
}
```